





CZECH REPUBLIC

Recent and planned developments in pharmaceutical policies 2017 Special topic: e-health for medicines launched by public authorities

D
Е
٧
Е
L
О
Р
M
Ε
N
Т
0

CHANGES IN PRICING

Changes in pricing of follow on products (see further clarification below)

CHANGES IN REIMBURSEMENT

 Ongoing 2nd and 3rd waves of complex reimbursement reviews

CHANGES IN PRICING AND REIMBURSEMENT

- An amendment to the Act No. 48/1997 Coll., on Public Health Insurance (since 1st April 2017):
 - The price and reimbursement of the first generic is cut down by 40 per cent (previously 32 per cent) against the price and reimbursement of the originator. Statutory price of the originator remains the same, but the reimbursement price is lowered to the price of the generic.
 - The price and reimbursement of the first biosimilar is cut down by 30 per cent (previously 15 per cent) of the originator. Statutory price of the originator remains the same, but the reimbursement price is lowered to the price of the biosimilar.
 - The price and reimbursement of the **second originator** (in case there is no generic or biosimilar) is cut down by 15 per cent (no change previously 15 per cent) against the first originator. Statutory price of the first originator remains the same, but the reimbursement price is lowered to the price of the second originator.

OTHER CHANGES

 An amendment of the Act No. 378/2007 Coll., on Pharmaceuticals (since 1st April 2017): Statutory measures to ensure availability of medicinal products on the Czech market – List of irreplaceable medicinal products that are subject to the export reporting.

E-HEALTH FOR MEDICINES

- Measure: eRecept (Electronic prescription)
- **Provided by:** SÚKL (State Institute for Drug Control)
- Aim: collect information on the medication of one patient
- Target group: patients, doctors, pharmacists
- Further information: mandatory since 1st January 2018 (currently obligatory only in case of medical cannabis)



L TOPIC

S

E C

Α